HCC; 2. Saracatinib; 3. Metastasis; Presenting Author: GUIHAI GUO Additional Authors: JIAN WANG Corresponding Author: GUIHAI GUO Affiliations: the first affiliated hospital of Nanchang University; The

First Affiliated hospital of Nanchang University Objective: The study was aimed to observe the efficacy of individual differences in treatment with tsanscatheter arterial chemoembolization (TACE) on primary hepatocellular carcinoma (PHC) with leukopenia, ascites, and portal vein tumor thrombus and cirrhosis. Methods: Analysis the Time to progression (TTP) and survival status of the 201 cases of PHC received TACE or TAC/TAE treatment during Apitolisib cell line June 2009 to June 2012. Only give the embolization of tumor feeding arteries, not use chemotherapy drugs in patients with neutropenia or ascites, cirrhosis. Comparative TTP, survival status and complications NU7441 concentration in TACE.

Results: 1. A total of 32 cases in the initial treatment of patients with WBC < 3.0 × 10 ∧ 9/L, and pre-treatment WBC average: 2.59 ± 0.34 × 10 ∧ 9/L, and the ALT: 38.22 ± 23.34 U/L, and AST: 62.19 ± 43.32 U/L, and TBIL: 18.50 ± 10.04 umol/L, ALB: 34.31 ± 5.29 g/L, A review of the results of the WBC after a month by only received lipiodol embolization is: 2.61 ± 0.30 × 10 ∧ 9/L, and the ALT: 37.38 ± 19.41 U/L, AST: 70.97 ± 47.66 U/L, TBIL: 17.94 ± 10.19 umol/L, ALB: 34.66 ± 4.91 g/L, differences were not statistically significant; There are 38% in patients with TTP of more than three month, three month survival rate was 78%, 6 month survival rate: 50%; 9 month survival rate: 22%; 12 month survival rate: 13%; median survival time for 6 months. 2. A total of 16 cases were associated with ascites, before treatment, the ALT: medchemexpress 33.94 ± 24.08 U/L, and AST: 82.25 ± 62.04 U/L, TBIL: 19.33 ± 11.15 umol The/L,, ALB,: 29.63 ± 2.58 g/L, A review of the results of the ALT after a month by only received lipiodol embolization is: 39.81 ± 21.05 U/L, AST: 59.69 ± 35.79 U/L, TBIL: 16.31 ± 5.19 umol/L, ALB:

35.19 ± 6.17 g/L, differences were not statistically significant; There are 19% of patients with TTP of more than three months, three month survival rate was 81%; 6 month survival rate: 31%; 9 month survival rate: 25%; 12 month survival rate: 13%; median survival time was 5.25 months. 3. A total of 65 patients with portal vein tumor thrombus, before treatment, the ALT: 36.59 ± 22.15 U/L, AST: 66.63 ± 44.00 U/L, TBIL: 16.30 ± 8.63 umol The/L, ALB,: 37.90 ± 5.16 g/L; Review the results of ALT after a month of TACE treatment is: 41.22 ± 19.80 U/L, AST: 67.21 ± 47.77 U/L, TBIL: 17.17 ± 8.25 umol/L, ALB,: 36.68 ± 4.52 g/L, the difference had no statistical significance; There are 22% of patients with TTP of more than three months, three month survival rate was 80%; 6 month survival rate: 43%; 9 month survival rate: 2%; 12 month survival rate: 0%; median survivaltime of 5.